ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1662

Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

Jemy Varghese1, Scott Canna1, Emily Landy2, Laurence Eisenlohr1, Elise Peauroi3, Vinh Dang1, Anastasia Frank-Kamenetskii4 and Jeremy Morrissette5, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA, 4CHOP/UPENN, Philadelphia, PA, 5University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA

Meeting: ACR Convergence 2023

Keywords: Cytotoxic Cells, innate immunity, Juvenile idiopathic arthritis, macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Pediatric Rheumatology – Basic Science

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS) are associated with highly elevated peripheral blood levels of the inflammasome-activated cytokine IL-18 and chronic exposure to free IL-18. IL-18 canonically acts on NK and activated T-cells in concert with other signals, like T-cell receptor engagement or IL-12 signaling, to amplify Interferon gamma (IFNg) production and cytotoxicity. We sought to determine the mechanisms by which excess IL-18 drives systemic hyperinflammation.

Methods: We assessed lymphocyte phenotypes, distribution, and function via flow cytometry and RNAseq in mice with transgenic expression of mature, secretable IL-18 (Il18tg) and relevant controls. Lymphocytic Choriomeningitis Virus (LCMV) Armstrong strain and ectromelia virus (ECTV) were injected intraperitoneally and via footpad, respectively. Cytokines were measured by bead array and viral quantitation by quantitative PCR. Data were analyzed using descriptive statistics.

Results: Like SJIA/MAS patients, Il18tg mice demonstrated decreased numbers of NK cells and a concomitant increase in activated CD8 T-cells in peripheral blood, spleen, and liver. Splenic and hepatic NK cells from Il18tg mice showed decreased IL-18 receptor expression, and were enriched for cell cycle and gene transcription programs, suggesting rapid cellular turnover possibly due to activation-induced cell death. Il18tg mice cleared (non-lytic) LCMV infection similarly to WT, but thereafter developed CD8 T-cell and IFNg-mediated immunopathology reminiscent of MAS. To directly challenge NK function in vivo, We infected Il18tg mice with ectromelia, which causes severe viral immunopathology in NK-depleted mice. In contrast to WT, NK cells from infected Il18tg mice neither expand nor upregulated activation markers. However, Il18tg mice managed virus similarly to WT mice at early timepoints. NK depletion impaired viral clearance in WT, but not Il18tg mice. As with LCMV, Il18tg mice developed MAS at 8-12 days post-infection, the peak of the CD8 T-cell response. As expected, WT mice largely cleared ectromelia between days 5 and 12. Il18tg mice showed robust CD8 T-cell expansion and activation, but nevertheless failed to significantly decrease ectromelia DNA (Fig. 1).

Conclusion: Thus, though chronic excess IL-18 both impairs NK cell numbers and IL-18 responsiveness, NK dysfunction appears irrelevant for the development of virus-triggered MAS. Chronic IL-18 excess may overcome NK dysfunction by “pre-priming” CD8 T-cell responses at early timepoints. However, excess IL-18 induced hyperinflammation to a variety of triggers, but only with the lytic ectromelia virus did excess IL-18 also causean unexpected, selective immunodeficiency most evident at the peak of CD8 T-cell expansion. Together, this suggests IL-18 may promote MAS by both CD8 T-cell cytokine amplification and an unexpected impairment of viral clearance.

Supporting image 1

Figure 1. (A) Representative flow plots of live liver immune cells from uninfected mice or at day 5 post-infection showing sustained NK deficiency and increased CD8 T-cells. (B) 18s rRNA normalized ectromelia viral DNA (Evm003) from spleen at the indicated timepoints. Significance was analyzed with a two-way ANOVA.


Disclosures: J. Varghese: None; S. Canna: Apollo Therapeutics, 2, Novartis, 12, Site PI for industry-sponsored trial, PracticePoint CME, 6, Simcha Therapeutics, 2, Sobi, 6; E. Landy: None; L. Eisenlohr: None; E. Peauroi: None; V. Dang: None; A. Frank-Kamenetskii: None; J. Morrissette: None.

To cite this abstract in AMA style:

Varghese J, Canna S, Landy E, Eisenlohr L, Peauroi E, Dang V, Frank-Kamenetskii A, Morrissette J. Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/chronic-excess-il-18-induces-nk-deficiency-but-drives-hyperinflammation-via-cd8-t-cell-cytokine-overproduction-and-selective-immunodeficiency/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-excess-il-18-induces-nk-deficiency-but-drives-hyperinflammation-via-cd8-t-cell-cytokine-overproduction-and-selective-immunodeficiency/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology